Neurocrine Biosciences Inc. announced that it will present new data from RE-KINECT, the largest real-world screening study to date of patients with clinician confirmed possible tardive dyskinesia (TD). This study is designed to better understand the potentially broad reaching impact of symptoms of possible TD on patients treated with antipsychotic medications.

Neurocrine will also present new data from the KINECT 4 study on long-term treatment with INGREZZA (valbenazine) capsules in participants with schizophrenia /schizoaffective disorder or mood disorder. INGREZZA is the first US Food and Drug Administration (FDA) approved treatment for adults with TD. These new data will be presented at the American Psychiatric Association (APA) Annual Meeting in New York City, May 5-9, 2018. New Data Provide Insight Into the Real-World Impact of Potential Tardive Dyskinesia in Patients Treated With Antipsychotic Medicines

Neurocrine is committed to understanding tardive dyskinesia and its impact on patients suffering with these symptoms, and improving the clinical care of this potentially underserved patient population," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine. "Data from the RE-KINECT study provide valuable insight into the impact of involuntary movements on the quality of life of patients and the heterogeneity of the patient population receiving antipsychotic medications who have the potential to be affected by tardive dyskinesia."

TD is characterised by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face, which may be disruptive and negatively impact patients. TD is associated with the prolonged use of medications that help control dopamine (a chemical in the brain), such as antipsychotics, used to treat conditions like depression, bipolar disorder and schizophrenia. TD is estimated to affect at least 500,000 people in the US

The seven Neurocrine-sponsored abstracts to be presented at the APA Annual Meeting are:

A Prospective Real-World Dyskinesia Screening Study and Registry in Patients Taking Antipsychotic Agents (RE-KINECT): Quality of Life Results ,RE-KINECT: A Prospective Real-World Dyskinesia Screening Study and Registry in Patients, Taking Antipsychotic Agents: Caregiver Burden Results ,Long-Term Valbenazine Treatment in Patients with Schizophrenia /Schizoaffective Disorder or Mood Disorder and Tardive Dyskinesia,Characteristics of Patients with Tardive Dyskinesia: Baseline Results from the KINECT 4 Valbenazine Study

A Delphi Approach to the Screening, Diagnosis, and Treatment of Tardive Dyskinesia,Results of a Depression and Bipolar Support Alliance Survey: Focused Analysis of Tardive Dyskinesia in Patients with Mood Disorders ,Characteristics of Patients with Mood Disorders Taking Antipsychotics: Data from Depression and Bipolar Support Alliance Survey Respondents

Tardive dyskinesia (TD) is characterised by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face. The condition is caused by treatments that block dopamine receptors in the brain, such as antipsychotics commonly prescribed to treat mental illnesses such as schizophrenia, bipolar disorder and depression and certain anti-nausea medications. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be severe and are often persistent and irreversible. TD is estimated to affect at least 500,000 people in the US

INGREZZA, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first FDA approved product indicated for the treatment of adults with tardive dyskinesia, a condition associated with uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face. INGREZZA is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function, helping to regulate nerve signaling in adults with tardive dyskinesia. VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. INGREZZA, developed in Neurocrine's laboratories, is novel in that it selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors. Additionally, INGREZZA can be taken for the treatment of tardive dyskinesia as one capsule, once-daily, together with psychiatric medications such as antipsychotics or antidepressants.